There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. After-hours trades for Forma Therapeutics Holdings Inc. (FMTX) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$0.12, or -0.60%, to $19.81. Volume reached 2,367 shares, with price reaching a high of $19.92 and a low of $19.92. The stock was recently discussed on Yahoo Finance as it revealed that Novo Nordisk to acquire Forma Therapeutics and expand presence in sickle cell disease and rare blood disorders.
This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. At the end of the last regular session, the stock closed at $19.92 and fluctuated between $19.96 as its day high and $19.92 as its day low. The current market capitalization of Forma Therapeutics Holdings Inc. is $953.77M. A total of 1.15 million shares were traded on the day, compared to an average of 1.33M shares.
Insider trades can also provide insight into a stock’s future direction. During the recent three months, FMTX has seen 1 BUY and 0 SELL insider trades, representing the acquisition of 79,000 and the disposition of 0 shares. Over the last 12 months, there were 18 BUYs and 7 SELLs from insiders. Insiders purchased 416,447 shares during that period but sold 45,637.
In the most recent transaction, Kelly Patrick F. sold 5,245 shares of FMTX for 9.78 per share on Feb 23. After the transaction, the SVP, Chief Medical Officer now owns 64,884 company shares. In a previous transaction on Feb 23, Lee Frank D. sold 17,981 shares at 9.78 per share. FMTX shares that President and CEO owns now total 79,769.
Among the insiders who sold shares, Potts Jeannette disposed of 4,672 shares on Feb 23 at a per-share price of $9.78. This resulted in the holding 22,358 shares of FMTX after the transaction. In another insider transaction, Shegog Todd sold 5,687 shares at $9.78 per share on Feb 23. Company shares held by the SVP, Chief Financial Officer now total 22,813.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. According to analysts who have offered 12-month price targets for FMTX in the last 3 months, the mean price target is $20.60 with high estimates of $23.00 and low estimates of $20.00. In terms of 52-week highs and lows, FMTX has a high of $24.99 and a low of $4.95.
As of this writing, FMTX has an earnings estimate of $-1.08 per share for the current quarter. EPS was calculated based on a consensus of 4 estimates, with a high estimate of $-1.02 per share and a lower estimate of $-1.12. The company reported an EPS of $-1.1 in the last quarter, which was -13.4% lower than expectations of $-0.97.
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects.
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 6 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for FMTX is Overweight with a score of 3.40. A total of 1 analysts rated the stock as Buy while 0 rated it as Overweight while 5 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.